Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Junghun | - |
dc.contributor.author | Kim, Hwan | - |
dc.contributor.author | Yu, Hana | - |
dc.contributor.author | Chung, Jae Yoon | - |
dc.contributor.author | Oh, Chang-Hyun | - |
dc.contributor.author | Yoo, Kyung Ho | - |
dc.contributor.author | Sim, Taebo | - |
dc.contributor.author | Hah, Jung-Mi | - |
dc.date.accessioned | 2024-01-20T19:34:22Z | - |
dc.date.available | 2024-01-20T19:34:22Z | - |
dc.date.created | 2021-09-01 | - |
dc.date.issued | 2010-03-01 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/131650 | - |
dc.description.abstract | The synthesis of a novel series of pyrimidin-4-yl-1H-imidazol-2-yl derivatives 7, 8, 9 and their antiproliferative activities against A375P human melanoma cell line and WM3629 cell line were described. Most compounds showed superior antiproliferative activities compared to Sorafenib, the well-known RAF inhibitor. Among them, 7a exhibited potent activities on both cell lines (IC50 = 0.62 and 4.49 mu M, respectively) and turned out to be a selective and potent CRAF inhibitor. (C) 2010 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.subject | MALIGNANT-MELANOMA | - |
dc.subject | BRAF | - |
dc.subject | KINASE | - |
dc.subject | INHIBITOR | - |
dc.subject | MUTATIONS | - |
dc.subject | CRAF | - |
dc.subject | SORAFENIB | - |
dc.subject | CANCER | - |
dc.subject | RAF | - |
dc.subject | ERK | - |
dc.title | Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmcl.2010.01.064 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, v.20, no.5, pp.1573 - 1577 | - |
dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
dc.citation.volume | 20 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1573 | - |
dc.citation.endPage | 1577 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000274714600023 | - |
dc.identifier.scopusid | 2-s2.0-76649090272 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | MALIGNANT-MELANOMA | - |
dc.subject.keywordPlus | BRAF | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | CRAF | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | RAF | - |
dc.subject.keywordPlus | ERK | - |
dc.subject.keywordAuthor | Pyrimidin-4-yl-1H-imidazol-2-yl derivatives | - |
dc.subject.keywordAuthor | Antiproliferative activity | - |
dc.subject.keywordAuthor | Melanoma cell line | - |
dc.subject.keywordAuthor | BRAF | - |
dc.subject.keywordAuthor | CRAF | - |
dc.subject.keywordAuthor | Selectivity | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.